UnitedHealth Group Faces Legal and Investigation Challenges

In February 2024, UnitedHealth Group chose not to respond when the Wall Street Journal reported that the Department of Justice had initiated an antitrust investigation into the company.

The detailed investigation highlighted by the Wall Street Journal, along with online healthcare data from the past year, serves as a key piece of evidence for shareholders suing the firm in federal court in Minnesota.

UnitedHealth is resisting various challenges.

Regarding claim rejections, the company argues that if claims are submitted on time with clear information, around 98% of all claims from eligible members will be paid. The rest, which are mostly unapproved, often involve services that do not meet criteria defined by relevant planning sponsors like employers or the Centers for Medicare and Medicaid Services.

In a separate case about Proton beam therapy and emergency care, UnitedHealth refuted the accusations but acknowledged that it had settled the lawsuit, admitting some misconduct. Following a cyberattack, the company claimed to have provided billions in support to healthcare providers affected by system disruptions due to hacks.

Relief managers at pharmacies, including those from UnitedHealth’s Optum RX division, contend that their methods have been misinterpreted, asserting that critics fail to recognize the checks that companies place on the influence of pharmaceutical firms in pricing. UnitedHealth also sought to dismiss the shareholder lawsuit, contesting the Justice Department’s allegations in the Amedisys case.